Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6526700 | 0.92 | PIK3CD (0.44) | PIK3CDPIK3CGMAOAPIK3R1CNR2 | |
| SCHEMBL6502889 | 0.90 | PIK3CD (0.43) | PIK3CDPIK3CGMAOAPIK3R1CNR2 | |
| SCHEMBL68154 | 0.77 | SLC6A9 (0.38) | CNR2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6030958 | 0.76 | MAPK1 (0.37) | CNR2MAPK1S1PR3 | |
| SCHEMBL6645382 | 0.74 | KMT2A (0.38) | NPC1RAB9AKMT2APTGFR | |
| SCHEMBL13913997 | 0.74 | ACACB (0.42) | NPC1RAB9AKMT2AMAPK1S1PR3 | |
| SCHEMBL69203 | 0.72 | CNR2 (0.37) | CNR2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL28975271 | 0.70 | KDM4C (0.43) | MEN1KMT2AS1PR3 | |
| SCHEMBL3457836 | 0.69 | PTGER4 (0.43) | CNR2MEN1RAB9AKMT2AS1PR3 | |
| SCHEMBL4614047 | 0.69 | CNR2 (0.35) | CNR2NPC1RAB9AMAPK1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020644-A1 | Bicyclic fused pyridinyl amides and advantagesous compositons thereof for use as fungicides | E.I. DU PONT DE NEMOURS AND COMPANY | 2005-01-27 | — | — | US | claimed |
| EP-1485372-A2 | BICYCLIC FUSED PYRIDINYL AMIDES AND ADVANTAGEOUS COMPOSITIONS THEREOF FOR USE AS FUNGICIDES | E. I. du Pont de Nemours and Company (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003080596-A2 | BICYCLIC FUSED PYRIDINYL AMIDES AND ADVANTAGEOUS COMPOSITIONS THEREOF FOR USE AS FUNGICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-10-02 | — | — | WO | claimed |
| US-20050020644-A1 | Bicyclic fused pyridinyl amides and advantagesous compositons thereof for use as fungicides | E.I. DU PONT DE NEMOURS AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| EP-1485372-A2 | BICYCLIC FUSED PYRIDINYL AMIDES AND ADVANTAGEOUS COMPOSITIONS THEREOF FOR USE AS FUNGICIDES | E. I. du Pont de Nemours and Company (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003080596-A2 | BICYCLIC FUSED PYRIDINYL AMIDES AND ADVANTAGEOUS COMPOSITIONS THEREOF FOR USE AS FUNGICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020644-A1 | Bicyclic fused pyridinyl amides and advantagesous compositons thereof for use as fungicides | CBR3, CBR1, PNPO | PIK3CD 1034/4885PIK3CG 734/4885MAOA 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.